| 注册
首页|期刊导航|中国现代中药|UPLC-MS/MS测定追风透骨丸中马兜铃酸类成分含量

UPLC-MS/MS测定追风透骨丸中马兜铃酸类成分含量

王颖 刘繁红 杨燕丽 何筱毅 何成军 杨蕾 袁军 戴忠

中国现代中药2023,Vol.25Issue(10):2207-2212,6.
中国现代中药2023,Vol.25Issue(10):2207-2212,6.DOI:10.13313/j.issn.1673-4890.20230208002

UPLC-MS/MS测定追风透骨丸中马兜铃酸类成分含量

Determination of Aristolochic Acids and Their Derivates in Zhuifeng Tougu Pills by UPLC-MS/MS

王颖 1刘繁红 1杨燕丽 1何筱毅 1何成军 1杨蕾 1袁军 1戴忠2

作者信息

  • 1. 四川省药品检验研究院 国家药品监督管理局中成药质量评价重点实验室,四川 成都 610097
  • 2. 中国食品药品检定研究院,北京 100050
  • 折叠

摘要

Abstract

Objective:To establish a method for determining the aristolochic acids and their derivates in Zhuifeng Tougu Pills by ultra-performance liquid chromatography-tandem mass spectrometry(UPLC-MS/MS).Methods:The gradient elution was carried out in the Waters ACQUITY UPLC HSS T3 column(100 mm×2.1 mm,1.8 μm)with acetonitrile-0.1%formic acid(containing 5 mmol·L-1 ammonium formate)as the mobile phase at a flow rate of 0.3 mL·min-1.Under electrospray ionization and multiple reaction monitoring(MRM)mode,the content was determined with the external standard method.Results:The 4 components showed a good linear relationship within 2-250 ng·mL-1(r>0.999).The average recovery of the 4 components was 104.2%,75.7%,112.0%,and 105.4%,respectively,at the addition amount of 20 ng·mL-1,and the relative standard deviations(RSDs)varied within the range of 1.9%-6.1%.The limits of quantitation(LOQs)were 0.002-0.100 μg·g-1.Aristolochic acids Ⅱ and Ⅲ were detected in none of the 7 batches of samples.The content of aristolochic acid Ⅰ and aristolactam Ⅰ in the samples was in the range of 0.09-0.41 μg·g-1 and 0.62-1.30 μg·g-1,respectively.Conclusion:The method is simple,sensitive,and reliable and can be applied to determination of aristolochic acid analogues in Zhuifeng Tougu Pills.

关键词

液相色谱-质谱法/多反应监测/马兜铃酸Ⅰ/马兜铃酸Ⅱ/马兜铃酸Ⅲ/马兜铃内酰胺Ⅰ/追风透骨丸

Key words

UPLC-MS/MS/MRM/aristolochic acid Ⅰ/aristolochic acid Ⅱ/aristolochic acid Ⅲ/aristolactam Ⅰ/Zhuifeng Tougu Pills

分类

医药卫生

引用本文复制引用

王颖,刘繁红,杨燕丽,何筱毅,何成军,杨蕾,袁军,戴忠..UPLC-MS/MS测定追风透骨丸中马兜铃酸类成分含量[J].中国现代中药,2023,25(10):2207-2212,6.

基金项目

国家药典委员会2021年度国家药品标准制修订研究课题(2021Z16) (2021Z16)

中国现代中药

OACSTPCD

1673-4890

访问量0
|
下载量0
段落导航相关论文